ES2064382T3 - Agente para el tratamiento de la enfermedad de raynaud. - Google Patents

Agente para el tratamiento de la enfermedad de raynaud.

Info

Publication number
ES2064382T3
ES2064382T3 ES89111000T ES89111000T ES2064382T3 ES 2064382 T3 ES2064382 T3 ES 2064382T3 ES 89111000 T ES89111000 T ES 89111000T ES 89111000 T ES89111000 T ES 89111000T ES 2064382 T3 ES2064382 T3 ES 2064382T3
Authority
ES
Spain
Prior art keywords
agent
treatment
raynaud disease
raynaud
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89111000T
Other languages
English (en)
Inventor
Shinichiro C O Daiichi Ashida
Kyoko C O Daiichi Seiya Sakuma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2064382T3 publication Critical patent/ES2064382T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE COMPUESTOS REPRESENTADOS POR LA FORMULA(I) EN DONDE R ES UN GRUPO IMIDAZOLILOTIAZOLILO O UNA PIRIDELO; N ES 1 O 2; Y M ES UN ENTERO ENTE 1 O 4, UNA SAL DE ESTO COMO UN INGREDIENTE ACTIVO, PARA PREPARAR UNA COMPOSICION FARMACEUTICA PARA TRATAR PROBLEMAS CIRCULATORIOS PERIFERICOS.
ES89111000T 1988-06-17 1989-06-16 Agente para el tratamiento de la enfermedad de raynaud. Expired - Lifetime ES2064382T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14944588 1988-06-17

Publications (1)

Publication Number Publication Date
ES2064382T3 true ES2064382T3 (es) 1995-02-01

Family

ID=15475275

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89111000T Expired - Lifetime ES2064382T3 (es) 1988-06-17 1989-06-16 Agente para el tratamiento de la enfermedad de raynaud.

Country Status (7)

Country Link
EP (1) EP0346929B1 (es)
JP (1) JPH0276814A (es)
KR (1) KR910000148A (es)
AU (1) AU627739B2 (es)
CA (1) CA1332357C (es)
DE (1) DE68914886T2 (es)
ES (1) ES2064382T3 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2080130A1 (en) * 1990-04-09 1991-10-10 Satoshi Kitamura Remedy for obstructive pulmonary diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61191612A (ja) * 1985-02-20 1986-08-26 Dai Ichi Seiyaku Co Ltd 虚血性心疾患用剤

Also Published As

Publication number Publication date
AU627739B2 (en) 1992-09-03
JPH0276814A (ja) 1990-03-16
DE68914886T2 (de) 1994-08-11
CA1332357C (en) 1994-10-11
DE68914886D1 (de) 1994-06-01
KR910000148A (ko) 1991-01-29
EP0346929B1 (en) 1994-04-27
EP0346929A3 (en) 1990-10-31
AU3648089A (en) 1989-12-21
EP0346929A2 (en) 1989-12-20

Similar Documents

Publication Publication Date Title
ES2063146T3 (es) Composiciones farmaceuticas que contienen acido n-(3,4-dimetoxicinamoil)-antranilico.
DE69529670T2 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
PT95826A (pt) Processo para a preparacao de composicoes farmaceuticas contendo como ingrediente activo acido r-alfa-liponico ou acido s-alfa-liponico
PT97689A (pt) Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
ES2088312T3 (es) Formulacion de liberacion controlada que contiene tramadol.
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
ATE188119T1 (de) Heilmittel für wunden und hämorrhoiden
IT1206341B (it) Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
AR019496A1 (es) Azalidas de 13 miembros, composiciones farmaceuticas, uso en la preparacion de medicamentos y preparacion de los mismos
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
ES2090083T3 (es) Derivados de cefalosporina, procedimiento para su preparacion y composicion antimicrobiana que contiene estos derivados.
ES2196049T3 (es) Uso de 2-(2-alquilfenilamino)oxazolinas y -tiazolinas para la fabricacion de un medicamento con efecto alfa 2 adrenergico.
ES8400742A1 (es) Procedimiento de preparacion de las dibenzooxepinas sustituidas y de sus sales de adicion con un acido mineral u organi-co.
ES502654A0 (es) Un procedimiento para la preparacion de nuevos derivados de 2-propanol
AR039895A1 (es) Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla
ES2129448T3 (es) Uso de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona en el tratamiento de tirosinemia y composiciones farmaceuticas.
ES2064382T3 (es) Agente para el tratamiento de la enfermedad de raynaud.
DE69805860T2 (de) Wasserlösliche ähnliche verbindungen und medicament-vorstufe von paclitaxel
GT199900171A (es) Concentrado oral de sertralina.
ES2118255T3 (es) Agente para uso como antiirritante.
AR005724A1 (es) Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple
MX9302818A (es) Agente para incrementar somatostatina o para inhibir la reduccion de somatostatina.
ES2105643T3 (es) Uso de la 2-(4-(4-clorofenil)ciclohexil)-3-hidroxi-1,4-naftoquinona para el tratamiento del cancer.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 346929

Country of ref document: ES